This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Example content
Adverse event reporting can be found at the bottom of the page
Prescribing information can be found at the bottom of the page.
Join us on Wednesday 24th June 2026 to hear from Dr Omar Khan, Consultant in Medical Oncology, Professor Rob Jones, Professor and Honorary Consultant, Dr Lynne Cormode, Specialist Doctor in Medical Oncology and Dr Balaji Venugopal, Consultant in Medical Oncology discussing 'TALZENNA® (talazoparib) + enzalutamide in mCRPC' followed by a live interactive Q&A.
This promotional meeting is organised and funded by Pfizer Ltd for UK HCPs and will include reference to medicines promoted by Pfizer.
Prescribing information can be found at the bottom of the page.
Join us on Wednesday 24th June 2026 to hear from Dr Omar Khan, Consultant in Medical Oncology, Professor Rob Jones, Professor and Honorary Consultant, Dr Lynne Cormode, Specialist Doctor in Medical Oncology and Dr Balaji Venugopal, Consultant in Medical Oncology discussing 'TALZENNA® (talazoparib) + enzalutamide in mCRPC' followed by a live interactive Q&A.
This promotional meeting is organised and funded by Pfizer Ltd for UK HCPs and will include reference to medicines promoted by Pfizer.
No Biography Available
Rob Jones is Professor of Clinical Cancer Research at the University of Glasgow and a Consultant medical oncologist at the Beatson West of Scotland Cancer Centre. He has a PhD in molecular biology and time spent working in Pharmaceutical Research and Development. His clinical practice is the medical management of cancers of the prostate and bladder and he has taken part in many of the groundbreaking drug trials in these diseases over the past 20 years. He is director of the Glasgow Oncology Clinical Trials Unit, and head of the Cancer Clinical Trials Unit for Scotland collaboration (CaCTUS). He is a past chair of the UK National Cancer Research Institute Bladder and Renal Cancer Research Group and the Advanced Prostate Cancer subgroup.
Dr Balaji Venugopal is a consultant in Medical Oncology at Beatson West of Scotland cancer centre and Honorary Clinical Associate Professor at University of Glasgow. He completed his specialist training in Medical Oncology within West of Scotland Deanery, Glasgow and during his training was awarded Doctorate in Medicine by University of Glasgow for his research in drug delivery.
Dr Venugopal was appointed as a Consultant in Medical Oncology in 2013 at Beatson West of Scotland Cancer Centre where he specialises in management of genito-urinary cancers including bladder, kidney, prostate and penile cancers. Dr Venugopal is the Team Lead for the Regional Uro-oncology Cancer at the Beatson, and he was the Chair of the West of Scotland Regional Renal Cancer Multidisciplinary Team.
Dr Venugopal is actively in involved in clinical research and is a chief investigator and principal investigator for multiple clinical trials urological cancers some which have been practice changing in the field of uro-oncology. He serves as a clinician expert in NICE and SMC technology appraisals and has been a member of National Cancer Research Institute renal cancer systemic therapies subgroup. He
has published his collaborative clinical research in high impact journals along with global peers.
Talzenna®(talazoparib tosylate)
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Pfizer Medical Information on 01304 616161.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2026 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-13971. December 2025